

VIRTUAL SUMMER CONFERENCE

THE NEW PARADIGM OF TREATMENT FOR THE HEADACHE PATIENT

AUG 20
28 20

DISCLOSURE

PROGRAM OVERVIEW

In the United States, 1.4 percent of all visits to office-based physicians are due to headache, which represents approximately 12 million physician visits in one year. According to recent studies, 8.7 million females and 2.6 million males in the US alone experience migraine. Existing and ongoing research activity in the field of headache has produced clinical data of which primary care providers should be cognizant in order to provide optimal care to headache sufferers. These data have significant implications for diagnosis and treatment and may challenge current assumptions about the role of healthcare professionals in the management of primary headache disorders. Practitioners should be knowledgeable about new findings concerning pharmacological agents used for the treatment of headache, including new formulations of existing medications and those recently available for headache management.

LEARNING OBJECTIVES

After participating in this educational activity, participants should be better able to

1. Incorporate the differential diagnoses of headache disorders in order to choose the best treatment strategies
2. Analyze safety and efficacy data for new and emerging therapies in the treatment of migraine
3. Develop and implement treatment plans in line with standards of practice for acute management of migraine
4. Develop and implement preventive treatment as migraine is progressing and transforming
5. Use effective therapeutic tools that address the gender-specific challenges of treating women with migraine

ACCREDITATION/DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Forefront Collaborative and Diamond Headache Clinic Research & Educational Foundation. Forefront Collaborative is accredited by the ACCME to provide continuing medical education for physicians.

ACCME

Forefront Collaborative designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP

The AAFP has reviewed The New Paradigm of Treatment for the Headache Patient and deemed it acceptable for up to 4.25 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 08/28/2020 to 08/28/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAP

Application for CME credit has been filed with the American Academy of Pediatrics. Determination of credit is pending.

VIRTUAL SUMMER CONFERENCE

THE NEW PARADIGM OF TREATMENT FOR THE HEADACHE PATIENT

AUG 20
28 20

DISCLOSURE

CERTIFICATES

To receive your CME certificate or your certificate of participation, you **MUST** complete the Forefront Collaborative online evaluation form. You may access the evaluation form at: <https://forefrontcollab.mededmanager.com/evaluation/number/54330>.

The evaluation opens on Friday, August 28, 2020, and must be completed by Saturday, August 28, 2021.

- ▶ Your certificate will generate in a new tab immediately upon completion of the evaluation, so be ready to print and/or save your certificate at that time
- ▶ A copy of your certificate will be emailed to you upon completion of the evaluation as well as be available in the account you created and can be accessed at any time in your dashboard

UNLABELED USE DECLARATION

During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.

STATEMENT OF DISCLOSURE AND INDEPENDENCE

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of the event.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

REVIEW COMMITTEE

In accordance with Forefront Collaborative policy, all content is reviewed by independent peer reviewers for balance, objectivity and commercial bias. The review committee includes the following reviewers/editors: **George Urban, MD (Chair); Jessica Ailani, MD; Mark Green, MD, FAAN; Stewart Tepper, MD**

FACULTY/PLANNING COMMITTEE DISCLOSURES

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

FACULTY: **Mark Green, MD, FAAN; Mark Greco, PT; Robert Kaniecki, MD; and Vincent Martin, MD**

PLANNERS: **Jacquelyn Fernandez and Leah Johnson**

VIRTUAL SUMMER CONFERENCE

THE NEW PARADIGM OF TREATMENT FOR THE HEADACHE PATIENT

AUG 28 | 2020

DISCLOSURE

The following individuals have disclosed that they and/or their spouse/partner have had a financial relationship in the past 12 months:

FACULTY

Jessica Ailani, MD

Consulting Fee: Amgen, Biohaven, Impel, Lilly, Lundbeck, Revance, Satsuma, Teva, and Zosano

Speakers Bureau: Allergan, Amgen, Biohaven, Lilly, Lundbeck, and Teva

Advisory Board: Allergan, Biohaven, Impel, Lilly, Teva, and Zosano

Contracted Research: Allergan, American Migraine Foundation, Biohaven, Lilly, and Zosano

Wade Cooper, DO

Consulting Fee: Alder, Amgen, Eli Lilly, Lundberg, and Teva

Advisory Board: Alder, Amgen, Eli Lilly, Lundberg, and Teva

Merle Diamond, MD

Consulting Fee: Alder, Amgen, Lilly, Promius, and Teva

Speakers Bureau: Amgen, Assertio Therapeutics, Lilly, Supernus, and Teva

Advisory Board: Alder, Amgen, Assertio Therapeutics, Lilly, Promius, Supernus, Teva, and Upsher-Smith Laboratories

Konrad Kothmann

Consulting Fee: Alder (Lundbeck), Allergan, Amgen, Lilly, Novartis, and Teva

Speakers Bureau: Allergan and Amgen

Advisory Board: Amgen, Lundbeck, and Novartis

Contracted Research: Alder (Lundbeck), Allergan, Amgen, Lilly, and Novartis

Stewart Tepper, MD

Consulting Fee: Acorda, Alder, Alexza, Align Strategies, Allergan, AlphaSights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy's, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion NeuroStim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano

Advisory Board: Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano

Contracted Research No Personal Compensation: Alder, Allergan, Amgen, Dr. Reddy's, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion NeuroStim, Teva, and Zosano

Ownership Interest, Excluding Diversified Mutual Funds-Stock Options: Percept

PLANNER

Lilia Zurkovsky

Stock Ownership: Teva